Drug
Ponatinib QD
Ponatinib QD: highest development phase Phase 3, developed by United Therapeutics. 1 trial record tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- United Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| Ponatinib 30 mg QD NCT02627677 | Phase 3 | Chronic Phase Chronic Myeloid Leukemia |
Latest
No recent events.
Follow Ponatinib QD on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.